Figure 7.

RP81-MNP decreases inflammatory response and injury markers and regulated necrosis. (A) Plasma levels of cytokines IL-1β, IL-6, TNFα, and KC in RNLS KO control mice and CKD mice treated with empty MNP or RP81-MNP. (B) Representative images of H&E-, TUNEL-, CD68-, and CD4-stained kidney sections at a magnification 400× from CKD mice treated with MNP (control) or RP81-MNP. (C) Stained CD68- and CD4-positive cells at the cortical medullary junction in the interstitial space of kidneys from CKD mice treated with control or RP81-MNP. Five high power field (400×) per mouse, three mice from each group, were counted. Occasional defined clusters of CD68-positive cells were encountered in the control CKD RNLS KO mice but never in the RP81-MNP administered CKD RNLS KO mice. (D and E) Immunoblotting analysis of protein isolated from kidneys at day 28 after two doses of cisplatin and with or without RP81-MNP treatment. Four individual mice per treatment group were analyzed on the blots. (F–K) Quantifications of immunoblots shown in (D) and (E). Differences were analyzed for significance using one way ANOVA corrected for multiple comparisons. *P<0.05; **P<0.001, ***P<0.0005, ****P<0.0001.